Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT 2022-02-28 21:00
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE 2022-02-07 21:00
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE 2022-01-25 21:00
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE 2022-01-07 21:00
KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER 2021-12-14 00:00
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma 2021-12-04 21:00
GBM AGILE Opens to Paxalisib in Canada 2021-11-29 22:05
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer 2021-11-16 00:00
PNOC Study in Childhood Brain Cancer Enrols First Patient 2021-11-11 21:00
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial 2021-11-04 08:38
Kazia Therapeutics to Present at LD Micro Main Event 2021-10-06 22:00
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference 2021-09-11 00:30
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day 2021-07-21 22:00
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs 2021-06-30 22:00
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma 2021-06-15 22:00
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient 2021-06-07 20:00
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE 2021-04-19 17:54
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company 2021-03-29 17:43
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB 2021-03-02 07:00
Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG 2020-12-10 12:51